Filing Details
- Accession Number:
- 0000904454-24-000391
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-20 20:31:31
- Reporting Period:
- 2024-06-17
- Accepted Time:
- 2024-06-20 20:31:31
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1426800 | Assembly Biosciences Inc. | ASMB | Biological Products, (No Disgnostic Substances) (2836) | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
882095 | Gilead Sciences, Inc. | 333 Lakeside Drive Foster City CA 94404 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-06-17 | 179,500 | $0.00 | 1,268,972 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrant to purchase Common Stock | Acquisiton | 2024-06-17 | 179,500 | $0.00 | 179,500 | $17.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
179,500 | 2029-06-18 | No | 4 | P | Direct |
Footnotes
- Pursuant to a securities purchase agreement between the Issuer and the Reporting Person, the Issuer issued and sold to the Reporting Person in a private placement 179,500 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), and a warrant to purchase 179,500 shares of Common Stock (the "Warrant") at a combined price of $15.46 per share of Common Stock and accompanying warrant.
- The Warrant is exercisable at any time after the date of issuance and expires on June 18, 2029. A holder of the Warrant may not exercise the Warrant if the holder, together with its affiliates, would beneficially own more than 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.